## HCA: HCA Healthcare, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -4.3% below STRENGTH zone (3.0-6.0%); PEG 1.22 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-7.4% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($461.49)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. How HCA Healthcare Stock Gained 60%**
- Source: Trefis | 20251202T073749 | Bullish | Relevance: 99%
- This article features the title "How HCA Healthcare Stock Gained 60%" and appears to be a stub or a placeholder for an interactive financial model. It outlines limitations for using the interactive model, such as the number of drivers that can be modified and value limits for current drivers. The content also notes that certain drivers cannot be modified if linked to a parent scenario.

**2. West Family Investments Inc. Makes New Investment in HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20251202T132414 | Bullish | Relevance: 99%
- West Family Investments Inc. has initiated a new position in HCA Healthcare, Inc. by purchasing 613 shares valued at approximately $235,000 in the second quarter. The article details HCA's strong Q3 earnings, positive FY2025 guidance, and recent institutional investor activity. It also covers analyst ratings and significant insider stock sales by HCA executives.

**3. Distillate Capital Partners LLC Has $21.01 Million Stock Holdings in HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20251202T100632 | Bullish | Relevance: 99%
- Distillate Capital Partners LLC reduced its holdings in HCA Healthcare Inc. by 26.5% in Q2, ending with 54,833 shares valued at approximately $21.01 million. HCA Healthcare exceeded Q3 earnings and revenue estimates, reporting $6.96 EPS and $19.16 billion in revenue, and set strong FY2025 guidance. Analysts maintain a bullish outlook with an average target price of $474.53, and the company recently declared a quarterly dividend of $0.72 per share.

**4. HCA Healthcare, Inc. $HCA Shares Sold by New York State Common Retirement Fund**
- Source: MarketBeat | 20251201T115105 | Neutral | Relevance: 99%
- The New York State Common Retirement Fund decreased its stake in HCA Healthcare by 5.5% in Q2, selling 18,346 shares and now owning 316,402 shares valued at $121.2 million. Despite this, HCA Healthcare reported strong quarterly earnings, beating analyst expectations with $6.96 EPS and $19.16 billion in revenue, and issued optimistic FY2025 guidance. Analysts maintain a "Moderate Buy" rating with a consensus price target of $474.53, while the company announced a quarterly dividend of $0.72 per share.

**5. HCAâ€™s Cash Machine Looks Cheap After A Healthy Run**
- Source: Finimize | 20251203T145120 | Somewhat-Bullish | Relevance: 99%
- HCA Healthcare, the largest for-profit hospital operator in the U.S., has shown strong recent performance with a 56.6% total return over 12 months and raised full-year guidance for 2025. Despite policy risks and labor cost inflation, its robust cash generation, strong margins, and perceived valuation discount make it an appealing opportunity for long-term investors, though the stock carries risks associated with leverage and regulatory uncertainty.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-13 | Wells Fargo | $431 | $412 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-13 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($3.12M) |
| Sells | 4 ($14.79M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 29.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 7 |

**Top Holders:**
- Vanguard Group Inc: 6.5% (-3.8%)
- Blackrock Inc.: 5.5% (-3.7%)
- Sanders Capital, LLC: 4.7% (-3.9%)
- State Street Corpora: 3.3% (-5.9%)
- JPMORGAN CHASE & CO: 2.6% (+82.2%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-7.4% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $15M sold (4 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.22 suggests fair value with growth premium. Forward P/E 16.4x stretched relative to 8% growth. Quality metrics strong (ROE 136%, ROA 12%). Balance sheet: $3.1B free cash flow. Insider selling cluster ($14.8M in 90 days), potential headwind. Institutional flow bullish (2 buying vs 7 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $114.3B |
| Beta | 1.37 |
| 52W Range | $289.98 - $520.00 |
| Short Interest | 2.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.22 |
| Forward P/E | 16.4 |
| Current P/E | 17.6 |
| YoY Growth | 7.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 3.1% to -4.3% (-7.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.3pp (needs >3.0% for momentum thesis). Underperforming sector by 4.1pp, stock-specific weakness. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-0.76), momentum weakening. RSI neutral at 55.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -4.32% (CS: 9) | Weak |
| RSI_14 | 54.8 | Neutral |
| MACD Histogram | -0.76 | Bearish |
| vs SMA20 | 1.004x | Above |
| vs SMA50 | 1.069x | Above |
| vs SMA200 | 1.260x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $486.77
- **Stop Loss:** $461.49 (5.2% risk)
- **Target:** $512.05 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 37
- **Position Value:** $18,010.49
- **Portfolio %:** 18.01%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite. VIX at 16 is below median, showing calm, but breadth is only moderate and put/call is neutral, suggesting neither strong bullish nor defensive extremes. Key drivers are rising Fed rate-cut odds from soft ADP jobs data, mixed earnings across sectors, and ongoing AI/tech strength offset by caution in cyclicals and banks. Positioning should remain selective and neutral, awaiting more decisive macro or earnings signals.*

### Earnings

**Next:** 2026-01-23 (Est: $7.46)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.73 | $6.96 | +21.6% |
| 2025Q2 | $6.32 | $6.84 | +8.2% |
| 2025Q1 | $5.75 | $6.45 | +12.1% |
| 2024Q4 | $6.14 | $6.22 | +1.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*